Strand Therapeutics

In short

Strand Therapeutics has 8 live jobs on Jobiba as of 7 November 2026. All of them are in the United States. Jobiba picked up 8 new postings from Strand Therapeutics in the last 30 days. The most posted roles are Associate Scientist, Senior Scientist and Principal Associate Scientist. 100% of the live job ads list pay.

Newest first

Strand Therapeutics jobs

Most posted roles

Associate Scientist2Senior Scientist2Principal Associate Scientist1Scientist1Senior / Principal Associate Scientist1Senior Vice President of Regulatory Sciences1

Pay

Strand Therapeutics salaries

100% of Strand Therapeutics's live ads list pay. Figures are the pay listed in Strand Therapeutics's own job ads; Jobiba publishes only role groups with enough ads.

Strand Therapeutics is a clinical-stage biotechnology company pioneering programmable mRNA therapeutics to unlock the full potential of genetic medicines. Strand is applying its proprietary Signal Stack platform, which integrates EverScript circular RNA, AmpliScript self-replicating RNA, SignalPath targeted delivery, and logic-driven SignalLock genetic circuits to enable precise control of therapeutic activity across tissues and cell types and overcome foundational limitations in targeting, durability, and safety. Strand is advancing a pipeline with an initial focus on oncology and autoimmune disease. Its initial program, STX-001, an intratumorally delivered LNP-encapsulated self-replicating RNA expressing IL-12, has demonstrated preliminary evidence of systemic immune activation and anti-tumor activity in patients with advanced solid tumors who have progressed on prior therapies. Building on this early clinical validation, intravenously delivered STX-003 is designed for tumor-targeted expression and avoidance of off-target expression. STX-003, which is expected to enter the clinic in mid-2026, has the potential to be a major step forward for the fields of genetic medicine and oncology. Strand is also advancing STX-005, an in vivo CAR-T program designed to enable controlled, durable expression and repeat dosing. Founded by MIT synthetic biology pioneers, Strand has raised over $250 million and is headquartered in Boston, MA.